Skip to main content

Table 7 Drug-likeness properties of the designed chromen-2-ones

From: Computational modeling, ligand-based drug design, drug-likeness and ADMET properties studies of series of chromen-2-ones analogues as anti-cancer agents

S/nos. MW HBA HBD mlogP SA ABS Lipinski violation Drug likeness
1. 514.61 6 1 3.49 4.83 0.55 1 Yes
2. 542.67 6 1 3.86 5.07 0.55 1 Yes
3. 557.68 6 1 3.34 5.24 0.55 1 Yes
4. 529.63 6 2 2.97 4.99 0.55 1 Yes
5. 583.72 6 1 3.7 4.96 0.55 1 Yes
6. 530.61 7 1 2.97 4.51 0.55 1 Yes
7. 543.65 6 1 3.15 4.66 0.55 1 Yes
8. 571.71 6 1 3.52 4.91 0.55 1 Yes
9. 569.69 6 1 3.52 4.83 0.55 1 Yes
10. 543.65 6 1 3.15 4.7 0.55 1 Yes
11. 559.65 8 2 2.38 5.15 0.55 1 Yes
12. 587.71 7 2 2.74 5.4 0.55 1 Yes
  1. MW, molecular weight; HBA, hydrogen bond acceptors; HBD, hydrogen bond donors; SA, synthetic accessibility; ABS, Bioavailability Score